US4670543A - Process for obtaining complex FVIII/vWF of therapeutical use and resulting products - Google Patents

Process for obtaining complex FVIII/vWF of therapeutical use and resulting products Download PDF

Info

Publication number
US4670543A
US4670543A US06/777,335 US77733585A US4670543A US 4670543 A US4670543 A US 4670543A US 77733585 A US77733585 A US 77733585A US 4670543 A US4670543 A US 4670543A
Authority
US
United States
Prior art keywords
fviii
complex
vwf
activity
process according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US06/777,335
Other languages
English (en)
Inventor
Alain Bourgois
Marylene Delezay
Vincent Fert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Oesterreichisches Institut fuer Haemoderivate
Immunotech SAS
Original Assignee
Immunotech SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunotech SAS filed Critical Immunotech SAS
Assigned to IMMUNOTECH, - A JOINT STOCK COMPANY reassignment IMMUNOTECH, - A JOINT STOCK COMPANY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: BOURGOIS, ALAIN, DELEZAY, MARYLENE, FERT, VINCENT
Application granted granted Critical
Publication of US4670543A publication Critical patent/US4670543A/en
Assigned to IMMUNO FRANCE SARL Z.I. reassignment IMMUNO FRANCE SARL Z.I. OPTION (SEE DOCUMENT FOR DETAILS). Assignors: IMMUNOTECH SA
Assigned to IMMUNO FRANCE SARL, A LIMITED LIABILITY COMPANY reassignment IMMUNO FRANCE SARL, A LIMITED LIABILITY COMPANY ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: IMMUNSTECH S.A.
Assigned to IMMUNO AKTIENGESELLSCHAFT FUR reassignment IMMUNO AKTIENGESELLSCHAFT FUR ASSIGNMENT OF ASSIGNORS INTEREST. Assignors: IMMUNO FRANCE SARL
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745Blood coagulation or fibrinolysis factors
    • C07K14/755Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • FMECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F16ENGINEERING ELEMENTS AND UNITS; GENERAL MEASURES FOR PRODUCING AND MAINTAINING EFFECTIVE FUNCTIONING OF MACHINES OR INSTALLATIONS; THERMAL INSULATION IN GENERAL
    • F16LPIPES; JOINTS OR FITTINGS FOR PIPES; SUPPORTS FOR PIPES, CABLES OR PROTECTIVE TUBING; MEANS FOR THERMAL INSULATION IN GENERAL
    • F16L55/00Devices or appurtenances for use in, or in connection with, pipes or pipe systems
    • F16L55/26Pigs or moles, i.e. devices movable in a pipe or conduit with or without self-contained propulsion means
    • HELECTRICITY
    • H04ELECTRIC COMMUNICATION TECHNIQUE
    • H04NPICTORIAL COMMUNICATION, e.g. TELEVISION
    • H04N5/00Details of television systems
    • H04N5/76Television signal recording
    • H04N5/91Television signal processing therefor
    • H04N5/92Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback
    • H04N5/9201Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal
    • H04N5/9206Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal
    • H04N5/9207Transformation of the television signal for recording, e.g. modulation, frequency changing; Inverse transformation for playback involving the multiplexing of an additional signal and the video signal the additional signal being a character code signal for teletext
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Definitions

  • This invention relates to the production of the FVIII/vWF complex for therapeutical use possessing both the antihaemophilic A activity and Willebrand activity as well as a high degree of purity.
  • antihaemophilic A activity is carried by the factor VIII (designated FVIII or VIII:C) which in the physiological state is associated with Willebrand factor (designated vWF or VIIIR:Ag) in form of the complex FVIII/wWF.
  • Factor VIII designated FVIII or VIII:C
  • Willebrand factor designated vWF or VIIIR:Ag
  • antihaemophilic factor A for therapeutical use which are most generally known and commercialized comprise:
  • cryoprecipitate which is obtained by thawing of the fresh blood plasma at 4° C.
  • cryoprecipitate which is very contaminated with fibrinogen
  • concentration of cryoprecipitate is of 5 to 10 international units (I.U.) per ml, while a value of 25 I.U. per ml can be obtained for the concentrate.
  • the concentrate possesses the disadvantage of being still strongly contaminated; the complex constitutes less than 10% of the total proteins of the concentrate.
  • the product obtained by these different processes consists of procoagulant factor VIII (FVIII:C) alone, therefore not containing said von Willebrand factor (vWF or VIIIR:Ag), such factor being required for people having Willebrand disease and that moreover such factor VIII isolated in this manner is not under its physiological form (which is normally the FVIII/vWF complex) wherein Willebrand factor serves both as transporter and protector of said factor VIII.
  • the saline buffers of elution used are generally not capable of dissociating an antigen-antibody bond.
  • the process in question is based on the well known principle of immunopurification (Immunoadsorbents in protein purification (E. Ruoslahti Ed., Sc. J. Immunol. 1976 Supplement No 3, pages 1 to 84--Characterization of a monoclonal antibody to human interferon and its use in affinity chromatography, Stenman et al., J. and Immunol. Meth. (1981) 46 p. 337-345).
  • immunopurification Immunoadsorbents in protein purification
  • factor VIII When its principle is applied in the particular case of factor VIII, it must be noted that the latter behaves in a very specific manner, i.e. it loses irreversibly its procoagulant activity in the elution solutions which are usually employed in immunopurification such as for example glycine hydrochloride, acetate buffer solution of low pH, KSCN and analogous conditions.
  • This invention proposes to respect both the procoagulant function of factor VIII and the integrity of the FVIII/wWF complex and its object is consequently a process characterized by including a fixation of the FVIII/vWF complex in physiological medium on a specific monoclonal antibody and releasing said complex by means of a suitable elution medium having no effect on the nature and the functions of such FVIII/vWF complex but able to dissociate the bonds linking the selected monoclonal antibody to the FVIII/vWF complex, thus collecting the latter in a highly purified form.
  • the antibody is bound to a solid carrier
  • the monoclonal antibody is selected among those to bind the FVIII/vWF complex in physiological medium and then to release such complex in the elution medium, the antibody itself not being denatured and recovering its capacity of fixing the FVIII/wWF complex after its return into the physiological medium thereby permitting repeated purification cycles;
  • the antibody responsive to the above definition is a monoclonal antibody derived from a hybridome selected after a series of hybridations of cells of mouse myelome X63 and mouse splenocytes BALB/C immunized with FVIII/vWF complex;
  • the elution medium is selected among the alkaline solution having a pH of between 8.5 and 10.5;
  • the alkaline solution is selected among the following bases: NaOH, NH 4 OH, ethanolamine, diethanolamine, triethanolamine and the like.
  • the antibodies anti-VIIIR:Ag are identified by means of von Willebrand factor (VIIIR:Ag) fixed on titration plate and of anti-mouse immunoglobulines goat antibody (marked by 125 iodine).
  • the antibodies anti-VIIIR:Ag identified as mentioned above are coupled to solid particles of the gel type and they are thereafter tested for their ability to bind the FVIII/vWF complex from plasma, resulting in the decrease of the antihaemophilic A and Willebrand activities tested in vitro.
  • the antibodies anti-VIIIR:Ag coupled with the solid particles and capable of fixing efficiently the FVIII/vWF complex are tested for their ability to release the FVIII/vWF complex in alkaline medium (pH 8.5 to 10.5); the eluted antihaemophilic A and von Willebrand activities are tested in vitro by the known processes.
  • the collected FVIII/vWF complex can be concentrated by a known process of ultrafiltration or aminohexyl-Sepharose chromatography; the process can be completed with a gel filtration step and/or a lyophilization step.
  • Splenocytes of BALB/c mouse hyperimmunized with complex FVIII/vWF were fused by means of polyethylene-glycol with cells of mouse myeloma (X63 cell line).
  • the hybridomas producing antibodies anti-VIIIR:Ag are selected and the produced antibodies are coupled with solid particles of Sepharose 4B type and tested:
  • the monoclonal antibody produced by the hybridoma selected as above is then placed in a suitable proteic medium and coupled with Sepharose 4B (dextrane polymer). A column of 1 liter is then filled with gel coupled with the antibody.
  • Sepharose 4B extracte polymer
  • the column equilibrated with sodium chloride 0.1M is loaded with 10 liters of plasma at a flow rate of 0.5 liter per hour.
  • the column is then washed with 2 liters of sodium chloride 0.1M, then eluted with 2 liters of triethanolamine, 100 mM (pH 9.9).
  • the whole of the active product is collected in 1 liter of eluent and contains about 5000 I.U. of factor VIII and of Willebrand factor, i.e. a yield of 50% and a concentration of 5 I.U. per ml. This product contains 100 times less contaminants than the cryoprecipitate and 10 times less than its concentrate.
  • the product can be concentrated up to 25 times (125 I.U. per ml) either by ultrafiltration or by aminohexyl-Sepharose chromatography.
  • triethanolamine as an elution buffer allows direct lyophilization of the eluted product. This facility also exists if other volatile bases (NH 4 OH, ethanolamine, diethanolamine or analogous compounds) are used.
  • the product resulting from the process is particularly suited to restore deficient activities in haemophilia A and von Willebrand patients through intravenous injection of small volume (500 I.U. in 4 ml).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Signal Processing (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Multimedia (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Combustion & Propulsion (AREA)
  • Zoology (AREA)
  • Mechanical Engineering (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
US06/777,335 1984-09-18 1985-09-18 Process for obtaining complex FVIII/vWF of therapeutical use and resulting products Expired - Lifetime US4670543A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR8414480 1984-09-18
FR8414480A FR2570276B1 (fr) 1984-09-18 1984-09-18 Procede d'obtention du complexe fviii/vwf a usage therapeutique et produits en resultant

Publications (1)

Publication Number Publication Date
US4670543A true US4670543A (en) 1987-06-02

Family

ID=9307917

Family Applications (1)

Application Number Title Priority Date Filing Date
US06/777,335 Expired - Lifetime US4670543A (en) 1984-09-18 1985-09-18 Process for obtaining complex FVIII/vWF of therapeutical use and resulting products

Country Status (9)

Country Link
US (1) US4670543A (de)
EP (1) EP0179006B1 (de)
JP (2) JPH0649720B2 (de)
AT (1) ATE69955T1 (de)
CA (1) CA1257211A (de)
DE (1) DE3584817D1 (de)
ES (1) ES8700568A1 (de)
FR (1) FR2570276B1 (de)
WO (1) WO1986001718A1 (de)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5252709A (en) * 1988-06-07 1993-10-12 Centre Regional De Transfusion Sanguine De Lille Chromatographic separation of plasma proteins
US5252710A (en) * 1990-08-02 1993-10-12 Association D'aquitaine Pour Le Developpment De La Transfusion Sanguine Et Des Recherches Hermatologiques Process for manufacturing von Willebrand factor
US5356878A (en) * 1987-12-21 1994-10-18 Miles Inc. Gel filtration of factor VIII
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
US6579723B1 (en) 1997-02-27 2003-06-17 Baxter Aktiengesellschaft Method of recovering highly purified vWF or factor VIII/vWF-complex
US20060068454A1 (en) * 2004-09-27 2006-03-30 Sysmex Corporation Method of inactivating blood coagulation factor and blood coagulation factor-inactivated sample
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3707213A1 (de) * 1987-03-06 1988-09-15 Behringwerke Ag Verfahren zur herstellung von faktor viii:c-mangelplasma und ein so erhaltenes mangelplasma
US5110907A (en) * 1989-08-01 1992-05-05 Alpha Therapeutic Corporation Factor viii complex purification using heparin affinity chromatography
JPH0427865A (ja) * 1989-12-21 1992-01-30 Kurita Water Ind Ltd 血液凝固因子用分離剤およびその製造方法
AT403991B (de) * 1990-04-04 1998-07-27 Atomic Austria Gmbh Alpinschi
AT403992B (de) * 1991-02-22 1998-07-27 Head Sport Ag Ski
AT403764B (de) 1996-03-15 1998-05-25 Immuno Ag Stabiler faktor viii/vwf-komplex
AT403765B (de) 1996-04-12 1998-05-25 Immuno Ag Verfahren zur herstellung einer präparation enthaltend einen hochgereinigten komplex

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4361509A (en) * 1981-12-14 1982-11-30 Scripps Clinic And Research Foundation Ultrapurification of factor VIII using monoclonal antibodies

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
Biological Abstracts, vol. 78, No. 8, 1984, Philadelphia, Pa., H. V. Stel et al; "Characterization of 25 Monoclonal Antibodies to Factor VIII-von Willebrand Factor: Relationship Between Ristocetin--Induced Platelet Aggregation and Platelet Adherence to Subendothelium": Blood 63(6): 1408-1415, 1984.
Biological Abstracts, vol. 78, No. 8, 1984, Philadelphia, Pa., H. V. Stel et al; Characterization of 25 Monoclonal Antibodies to Factor VIII von Willebrand Factor: Relationship Between Ristocetin Induced Platelet Aggregation and Platelet Adherence to Subendothelium : Blood 63(6): 1408 1415, 1984. *
Chem. Abstracts, vol. 103, No. 5, p. 376, 1985, Columbus, Ohio, P. Avner et al. "Monoclonal Anitbodies Against the Human Factor VIII von Willebrand Molecule: Characterization and Potential for Screening of von Willebrand Patients" Dev.Biol.Stand. 1984.
Chem. Abstracts, vol. 103, No. 5, p. 376, 1985, Columbus, Ohio, P. Avner et al. Monoclonal Anitbodies Against the Human Factor VIII von Willebrand Molecule: Characterization and Potential for Screening of von Willebrand Patients Dev.Biol.Stand. 1984. *
Chemical Abstracts, vol. 96, No. 19, May 10, 1982, p. 571, No. 160565y, Columbus, Ohio, US; D. N. Fass et al.: "Monoclonal Antibodies to Porcine Factor VIII Coagulant and Their Use in the Isolation of Active Coagulant Protein".
Chemical Abstracts, vol. 96, No. 19, May 10, 1982, p. 571, No. 160565y, Columbus, Ohio, US; D. N. Fass et al.: Monoclonal Antibodies to Porcine Factor VIII Coagulant and Their Use in the Isolation of Active Coagulant Protein . *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5543145A (en) * 1984-09-17 1996-08-06 Baxter International, Inc. Pharmaceutical composition and method for the suppression of factor VIII inhibitor production
US8597910B1 (en) 1985-04-11 2013-12-03 Children's Medical Center Corporation DNA encoding Von Willebrand Factor (VWF) and methods and cells for producing VFW, and VFW produced by the DNA, methods and cells
US5356878A (en) * 1987-12-21 1994-10-18 Miles Inc. Gel filtration of factor VIII
US5252709A (en) * 1988-06-07 1993-10-12 Centre Regional De Transfusion Sanguine De Lille Chromatographic separation of plasma proteins
US5760183A (en) * 1989-02-17 1998-06-02 Association D'aquitaine Pour De Developpment De La Transfusion Sanguine Et Des Recherches Hematologiques Process for the manufacture of very high-purity antithaemophilic factor (FVIIIC), and von Willebrand factor, and pharmaceutical compositions containing same
US5252710A (en) * 1990-08-02 1993-10-12 Association D'aquitaine Pour Le Developpment De La Transfusion Sanguine Et Des Recherches Hermatologiques Process for manufacturing von Willebrand factor
US6579723B1 (en) 1997-02-27 2003-06-17 Baxter Aktiengesellschaft Method of recovering highly purified vWF or factor VIII/vWF-complex
US20060068454A1 (en) * 2004-09-27 2006-03-30 Sysmex Corporation Method of inactivating blood coagulation factor and blood coagulation factor-inactivated sample
US20090092958A1 (en) * 2004-09-27 2009-04-09 Sysmex Corporation Method of Inactivating Blood Coagulation Factor and Blood Coagulation Factor-Inactivated Sample

Also Published As

Publication number Publication date
ES8700568A1 (es) 1986-10-16
JPH0649720B2 (ja) 1994-06-29
WO1986001718A1 (fr) 1986-03-27
EP0179006B1 (de) 1991-12-04
ATE69955T1 (de) 1991-12-15
JPH06107700A (ja) 1994-04-19
JPS62500520A (ja) 1987-03-05
FR2570276B1 (fr) 1987-09-04
DE3584817D1 (de) 1992-01-16
FR2570276A1 (fr) 1986-03-21
ES547051A0 (es) 1986-10-16
CA1257211A (fr) 1989-07-11
EP0179006A1 (de) 1986-04-23
JPH06102680B2 (ja) 1994-12-14

Similar Documents

Publication Publication Date Title
EP0083483B2 (de) Ultragereinigte Faktor VIII : C-Zubereitung
US4749780A (en) Biologically active fragments of human antihemophilic factor and method for preparation thereof
US4670543A (en) Process for obtaining complex FVIII/vWF of therapeutical use and resulting products
RU1837880C (ru) Способ разделени белков крови
Fulcher et al. Characterization of the human factor VIII procoagulant protein with a heterologous precipitating antibody.
US4568488A (en) Reverse immunoaffinity chromatography purification method
JP2631127B2 (ja) フォン・ビルブラント因子の▲viii▼因子結合ドメイン
EP0561427B1 (de) Monoklonale Antikörper gegen neue Faktor-VIII Gerinnungspolypeptide
US4902618A (en) Production of hybridoma antibodies for interferon
JPH05268985A (ja) モノクローナル抗体の精製法
US6579723B1 (en) Method of recovering highly purified vWF or factor VIII/vWF-complex
Schneider et al. Characterization of ligand-binding activity of isolated murine Fc gamma receptor.
Timpl et al. Immunogenicity and specificity of collagen: VI. Separation of antibody fractions with restricted specificity from anticollagen sera using an immunoadsorbent technique
EP0253331B1 (de) Throminbindende Substanz und Verfahren zu ihrer Herstellung
JP2001506987A (ja) フォンビルブラント因子誘導体及びタンパク質の単離法
US20020019036A1 (en) Von willebrand factor derivatives and methods of isolating proteins that bind to von willebrand factor
EP0217061B1 (de) Ultrareinigung des Faktors VIII
JP2639684B2 (ja) 抗cpb▲ii▼モノクローナル抗体
Muensch et al. A monoclonal antibody to hemoglobin F
CA1251152A (en) Ultrapurification of factor viii
NO300895B1 (no) Fremgangsmåte for rensing av et humant rå-leukocyttinterferon
JPH01258700A (ja) 血液凝固第4因子の精製方法

Legal Events

Date Code Title Description
AS Assignment

Owner name: IMMUNOTECH, 70, ROUTE LEON-LACHAMP - CASE 915-LIMI

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNORS:BOURGOIS, ALAIN;DELEZAY, MARYLENE;FERT, VINCENT;REEL/FRAME:004480/0240

Effective date: 19850926

STCF Information on status: patent grant

Free format text: PATENTED CASE

AS Assignment

Owner name: IMMUNO FRANCE SARL Z.I. SENIA 544, 8, RUE DES QUIN

Free format text: OPTION;ASSIGNOR:IMMUNOTECH SA;REEL/FRAME:004839/0101

Effective date: 19870913

Owner name: IMMUNO FRANCE SARL Z.I.,FRANCE

Free format text: OPTION;ASSIGNOR:IMMUNOTECH SA;REEL/FRAME:004839/0101

Effective date: 19870913

AS Assignment

Owner name: IMMUNO FRANCE SARL, A LIMITED LIABILITY COMPANY

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:IMMUNSTECH S.A.;REEL/FRAME:004979/0076

Effective date: 19881025

FEPP Fee payment procedure

Free format text: PAYOR NUMBER ASSIGNED (ORIGINAL EVENT CODE: ASPN); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

FPAY Fee payment

Year of fee payment: 4

FEPP Fee payment procedure

Free format text: PAT HLDR NO LONGER CLAIMS SMALL ENT STAT AS SMALL BUSINESS (ORIGINAL EVENT CODE: LSM2); ENTITY STATUS OF PATENT OWNER: LARGE ENTITY

AS Assignment

Owner name: IMMUNO AKTIENGESELLSCHAFT FUR, CHEMISCH-MEDIZINISC

Free format text: ASSIGNMENT OF ASSIGNORS INTEREST.;ASSIGNOR:IMMUNO FRANCE SARL;REEL/FRAME:005650/0788

Effective date: 19901204

FPAY Fee payment

Year of fee payment: 8

FPAY Fee payment

Year of fee payment: 12